Search

Displaying results 5931 - 5940 of 6279 in total
  1. Drug

    Influenza B virus B/Maryland/15/2016 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14591
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  2. Drug

    Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14592
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  3. Drug

    Influenza B virus B/Maryland/15/2016 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14593
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  4. Drug

    Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14602
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  5. Drug

    Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14603
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  6. Drug

    Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14608
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  7. Drug

    Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14610
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  8. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14611
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

    Synonyms: Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (UV, formaldehyde inactivated)
  9. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14612
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  10. Drug

    Influenza A virus A/Uruguay/716/2007(H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14615
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it